Zoetis assumed with a Buy at Jefferies

Jefferies assumed coverage of Zoetis with a Buy rating and $230 price target, calling the company the “premier animal health player” with strong underlying fundamentals. The debate against Zoetis is always “it’s expensive,” but the firm argues that the company boasts consistent above animal health market growth, “attractive” margins and EPS, low leverage and a commitment to shareholder return.